Posts

Proteintech Launches AI-Driven Antibody Selection Platform “Able”

Proteintech, a supplier of antibodies and life science research tools, has released Able, an artificial intelligence–based platform designed to streamline antibody selection and experimental...

New AI-Driven Framework Improves Prediction of ccRCC Treatment Response

Clear cell renal cell carcinoma (ccRCC) remains one of the most difficult cancers to treat effectively, in part because no single biomarker has reliably...

A conserved central element protein links synaptonemal complex assembly and crossover regulation in plants

Homologous recombination during meiosis generates genetic diversity while ensuring chromosome segregation. The repair of DNA double-strand breaks into crossovers (COs) is tightly regulated, and...

Altasciences and Evidence Matters Announce Strategic Collaboration to Advance AI-Enhanced Text Engineering for Regulatory Writing in Life Sciences

Altasciences, a contract research and manufacturing organization specializing in early-phase drug development, has announced a collaborative effort with Evidence Matters to advance methods in...

Transcriptional control of regulatory B-1a cells by TCF1 and LEF1

B-1a cells occupy a distinctive niche within the B cell lineage, characterized by early-life development, self-renewal, and potent immunoregulatory functions. Their presence in humans...

Tempus Announces the Acquisition of Paige

Tempus AI, a company focused on applying artificial intelligence (AI) in precision medicine, has announced the acquisition of Paige, an organization specializing in AI...

Twist Bioscience Launches Oncology DNA CGP Panel to Advance Precision Medicine

Twist Bioscience has developed a customizable DNA-based comprehensive genomic profiling (CGP) panel intended for research applications in oncology. The panel enables the identification of...

BioSkryb Genomics secures license for integrated single-cell methylation and genome variation analysis

BioSkryb Genomics has obtained an exclusive license to a patent co-owned by Stanford University and the Chan Zuckerberg Biohub San Francisco (CZ Biohub SF),...

N-Power Medicine introduces a prospective external control arm platform to accelerate oncology drug development

The design of oncology clinical trials has long been constrained by the reliance on randomized controlled trials, which, while scientifically rigorous, often entail high...

Decoding and Reprogramming the Biosynthetic Networks of Ganoderma Metabolites

Ganoderma lucidum, a renowned medicinal mushroom, produces a diverse array of triterpenoids with pharmacological potential. Yet, the underlying biosynthetic logic of these specialized metabolites,...